2. Academic Validation
  3. H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts

H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts

  • Exp Ther Med. 2020 Aug;20(2):846-853. doi: 10.3892/etm.2020.8765.
Junko Takei 1 2,  Mika Kato Kaneko 1,  Tomokazu Ohishi 3,  Manabu Kawada 3,  Hiroyuki Harada 2,  Yukinari Kato 1 4
Affiliations

Affiliations

  • 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
  • 2 Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
  • 3 Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu-shi, Shizuoka 410-0301, Japan.
  • 4 New Industry Creation Hatchery Center, Tohoku University, Sendai, Miyagi 980-8575, Japan.
PMID: 32765652 DOI: 10.3892/etm.2020.8765
Abstract

Human epidermal growth factor receptor 2 (HER2) is reported to be overexpressed in breast cancers and is associated with poor clinical outcome. Trastuzumab is a humanized anti-HER2 antibody that offers significant survival benefits to patients with HER2-overexpressing breast Cancer. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, kappa) was developed. Antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antitumor activity of H2Mab-19 were investigated using both breast Cancer and oral Cancer cell lines. H2Mab-19 demonstrated cytotoxicity in BT-474 (a human breast Cancer cell line) and HSC-2 or SAS (human oral Cancer cell lines). H2Mab-19 also possessed both ADCC and CDC activity against BT-474, HSC-2, and SAS cell lines. In comparison to control mouse IgG, H2Mab-19 significantly reduced tumor development in BT-474, HSC-2, and SAS xenografts. Collectively, these results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing breast and oral cancers.

Keywords

HSC-2; antitumor activity; monoclonal antibody.

Figures
Products